Bioethicists Say Right-to-Try Legislation Will Have Minimal Effect on Drug Access

Drug Industry Daily
Federal right-to-try legislation passed in the Senate and now awaiting a vote in the House would only minimally benefit patient access to investigational drugs and would delay the FDA’s approval process for new drugs, according to bioethicists at the University of Pennsylvania’s Department of Medical Ethics.

To View This Article:


Subscribe To Drug Industry Daily